Literature DB >> 184011

Male pseudohermaphroditism consistent with 17,20-desmolase deficiency.

U Goebelsmann, M Zachmann, V Davajan, R Israel, J H Mestman, D R Mishell.   

Abstract

A 16-year-old phenotypic female with XY genotype presented an unusual form of nonfamilial male pseudohermaphroditism. Seemingly a normal girl during childhood, the patient failed to undergo pubertal changes presenting with scant pubic hair, absent axillary hair, lack of breast development, retarded bone age and primary amenorrhea. Neither uterus nor adnexa were palpable above the blind-ending vagina. Serum testosterone and estradiol were barely detectable by radioimmunoassay, while LH and FSH reached castrate levels. Two small testes were removed from the pelvic sidewalls which, on biopsy, showed atrophy and hyalinization of seminiferous tubules, but clusters of Leydig cells without signs of hypertrophy or hyperplasia. Administration of testosterone resulted in urinary nitrogen retention and a decrease in serum LH and FSH. Radioimmunoassay of various serum or plasma steroids and gas chromatographic determination of urinary steroids prior to and following ACTH stimulation yielded results which permitted to rule out 20,22-desmolase, 3beta-hydroxysteroid dehydrogenase, 17-hydroxylase and 17beta-hydroxysteroid dehydrogenase deficiency. Low plasma dehydroepiandrosterone sulfate (DHEA-S) and androstenedione (delta4 A) concentrations, low urinary 17-ketosteroid and particularly low dehydroepiandrosterone (DHEA) excretion and the minimal rise of plasma DHEA-S and delta4 A and of urinary DHEA in response to ACTH in conjunction with a normal response of other serum and urinary C-21 steroids are consistent with 17,20-desmolase deficiency. Direct confirmation of this defect, however, seems impossible in the absence of in vitro studies of testicular steroidogenesis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 184011     DOI: 10.1159/000301330

Source DB:  PubMed          Journal:  Gynecol Invest        ISSN: 0017-5986


  9 in total

Review 1.  The syndrome of 17,20 lyase deficiency.

Authors:  Walter L Miller
Journal:  J Clin Endocrinol Metab       Date:  2011-11-09       Impact factor: 5.958

2.  Familial male pseudohermaphroditism.

Authors:  A C Ammini; D C Sharma; R Gupta; I Mohapatra; K Kucheria; A Kriplani; D Takkar; D K Mitra; M Vijayaraghavan
Journal:  Indian J Pediatr       Date:  1997 May-Jun       Impact factor: 1.967

Review 3.  Endocrine findings in male pseudohermaphroditism.

Authors:  M Zachmann
Journal:  Eur J Pediatr       Date:  1993       Impact factor: 3.183

4.  Comments on some genetic abnormalities of sex determination and sex differentiation in Homo sapiens.

Authors:  J M Opitz
Journal:  Eur J Pediatr       Date:  1980-03       Impact factor: 3.183

5.  Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues.

Authors:  B C Chung; J Picado-Leonard; M Haniu; M Bienkowski; P F Hall; J E Shively; W L Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

6.  Partial 17, 20-desmolase and 17 alpha-hydroxylase deficiencies in a 16-year-old boy.

Authors:  D Bosson; R Wolter; M Toppet; J R Franckson; E de Peretti; M G Forest
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

7.  Male pseudohermaphroditism: genetics and clinical delineation.

Authors:  J L Simpson
Journal:  Hum Genet       Date:  1978-10-19       Impact factor: 4.132

8.  A missense mutation in the human cytochrome b5 gene causes 46,XY disorder of sex development due to true isolated 17,20 lyase deficiency.

Authors:  Jan Idkowiak; Tabitha Randell; Vivek Dhir; Pushpa Patel; Cedric H L Shackleton; Norman F Taylor; Nils Krone; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

9.  Assessment of testicular testosterone production and Leydig cell structure.

Authors:  L L Ewing; B R Zirkin; C Chubb
Journal:  Environ Health Perspect       Date:  1981-04       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.